Medtronic has scored FDA approval for its Visia AF MRI SureScan and AF implantable cardioverter defibrillators, the device giant announced Monday.
The atrial fibrillation (AF) systems are designed to treat previously undiagnosed and/or aymptomatic AF, monitor recurrent AF and treat “life-threatening” rhythms located in the lower chambers, according to the company.
The devices feature an algorithm that pinpoints AF episodes and captures AF frequency. A product launch is expected in early summer. — Anisa Jibrell